TY - JOUR T1 - Development of machine learning model for predicting hospitalization in the prehospital setting JF - medRxiv DO - 10.1101/2021.11.29.21266929 SP - 2021.11.29.21266929 AU - Kenichiro Morisawa AU - Tadahiro Goto AU - Shigeki Fujitani Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/30/2021.11.29.21266929.abstract N2 - Background Studies have developed models for predicting patient outcomes for successful risk stratification in the prehospital setting. However, these models generally require many predictors to achieve high prediction ability, resulting in a bar for implementing models in the real clinical setting.Objective We aimed to develop a simple and implementable machine learning model using automatically-collected data (age, sex, vital signs) to predict patient outcomes during transportation in comparison with National Early Warning Score (NEWS).Methods This is a retrospective cohort study using data from the ED of three tertiary care hospitals in Japan from April 2017 to March 2020. We included adult patients (aged ≥18 years) who were transported to the ED of participating hospitals. We excluded patients with trauma/injury, cardiac arrest, transferred from other hospitals, patients with missing vital signs data, or having data of obvious outliers. The predictors were patient age, sex, mental status evaluated with Japan Coma Scale, systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate, and oxygen saturation. The primary outcome was hospitalization. We developed a model using XGBoost.Results During the study period, 3528 visits transported by emergency medical services were eligible. The median NEWS was 4.0, and 2081 patients were hospitalized. The discrimination ability of the newly developed model was 0.70 (95%CI 0.67-0.73), which was better than those of NEWS 0.64 (95%CI 0.61-0.68). The newly developed model’s performance measures (e.g., sensitivity, specificity) were comparable with NEWS.Conclusions Our newly developed machine learning model using routinely available data has moderate prediction ability and was better than NEWS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Japan Agency for Medical Research and Development.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethics Committee of TXP Medical Co., Ltd., and the requirement for informed consent was waived due to the retrospective nature of the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -